TMBR - Timber Pharmaceuticals, Inc. Stock Price, Fair Value and News

0USD0Market Closed

TMBR Stock Price

View Fullscreen

TMBR RSI Chart

TMBR Valuation

EV/EBITDA

0.13

TMBR Price/Sales (Trailing)

TMBR Profitability

EBT Margin

-23289.91%

Return on Equity

-27.85%

Return on Assets

-449%

TMBR Fundamentals

TMBR Revenue

Revenue (TTM)

83.2K

TMBR Earnings

Earnings (TTM)

-14.9M

Breaking Down TMBR Revenue

Last 90 days

-100%

Trailing 12 Months

-100%

How does TMBR drawdown profile look like?

TMBR Financial Health

Current Ratio

0.5

TMBR Investor Care

Shares Dilution (1Y)

16.51%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	929.0K	540.2K	273.2K	83.2K
2021	467.6K	856.5K	798.9K	886.5K
2020	302.4K	297.4K	404.4K	453.8K
2019	57.0K	0	256.6K	285.5K
2018	73.0K	72.0K	79.0K	71.0K
2017	100.0K	86.0K	84.0K	69.0K
2016	64.0K	93.0K	107.0K	120.0K
2015	53.7K	56.3K	58.8K	61.4K
2013	25.5K	25.6K	51.1K	0
2012	41.5K	34.6K	27.8K	28.5K
2011	0	0	55.2K	48.3K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Timber Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 20, 2023	mendelsohn alan	acquired	-	-	35,193	evp & cmo
Aug 20, 2023	lucchese joseph	acquired	-	-	35,193	evp & cfo
Aug 20, 2023	koconis john	acquired	-	-	70,385	ceo & chairman
Apr 15, 2023	gaal lubor	acquired	-	-	4,100	-
Apr 15, 2023	pirozzi gianluca	acquired	-	-	4,100	-
Apr 15, 2023	sitar edward j	acquired	-	-	5,327	-
Apr 15, 2023	cohen david e	acquired	-	-	4,100	-
Dec 15, 2022	sitar edward j	acquired	4,072	1.629	2,500	-
Apr 15, 2022	cohen david e	acquired	-	-	100,000	-
Apr 15, 2022	pirozzi gianluca	acquired	-	-	100,000	-

Which funds bought or sold TMBR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Future Financial Wealth Managment LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-115,094	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-48,374	-	-%
Feb 14, 2024	PenderFund Capital Management Ltd.	sold off	-100	-391,000	-	-%
Feb 14, 2024	Tudor Investment Corp Et Al	sold off	-100	-746,835	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-42,965	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-66,344	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-5,346	-	-%
Feb 13, 2024	Yakira Capital Management, Inc.	sold off	-100	-78,439	-	-%
Feb 09, 2024	UBS Group AG	sold off	-100	-4,936	-	-%

Are Funds Buying or Selling TMBR?

Are funds buying TMBR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMBR

No. of Funds

Unveiling Timber Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 15, 2022	intracoastal capital, llc	4.2%	5,763,596	SC 13G
Feb 14, 2022	altium capital management lp	4.99%	2,539,063	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	3.88%	2,574,834	SC 13G/A
Jan 18, 2022	empery asset management, lp	4.99%	9,866,540	SC 13G/A
Sep 09, 2021	tardimed sciences llc	9.0%	3,308,567	SC 13D/A
Sep 01, 2021	tardimed sciences llc	10.2%	3,733,567	SC 13D/A
Aug 27, 2021	tardimed sciences llc	11.3%	4,134,067	SC 13D/A
Jun 11, 2021	tardimed sciences llc	13.0%	4,783,982	SC 13D/A
Feb 16, 2021	altium capital management lp	9.99%	206,875	SC 13G/A
Feb 11, 2021	hudson bay capital management lp	9.99%	1,335,447	SC 13G

Recent SEC filings of Timber Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Feb 22, 2024	8-K	Current Report

Peers (Alternatives to Timber Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Timber Pharmaceuticals, Inc. News

Latest updates

Timber Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-	-	-	-	83,177	190,005	266,974	388,819	40,734	102,382	324,521	-	26,907	52,922	217,616	5,000	10,000	24,000	18,000	19,000	18,000	17,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	-50,000	11,000	11,000	-203,000	10,000	8,000
Operating Expenses	14.0%	3,566,180	3,127,196	9,403,843	3,221,354	2,994,897	3,270,834	3,356,112	1,914,907	2,332,811	1,919,056	14,273,877	2,664,867	392,691	794,995	3,226,000	4,402,000	-	-	-	-	-
S&GA Expenses	9.6%	1,465,209	1,336,668	1,512,343	1,702,395	1,469,122	1,296,641	1,556,012	1,065,389	1,471,356	1,233,849	1,055,084	456,794	114,492	235,307	440,000	550,000	-	-	-	-	-
R&D Expenses	17.3%	2,100,971	1,790,528	3,891,500	1,518,959	1,525,775	1,974,193	1,800,100	849,518	955,534	685,207	536,170	1,018,231	469,199	539,688	1,794,000	2,228,000	-	-	-	-	-
EBITDA Margin	-500.1%	-231	-38.51	-19.48	-11.33	-11.87	-18.62	-17.37	-31.81	-32.78	-21.91	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	1,000	-	-
Earnings Before Taxes	-	-	-	-	-3,073,394	-	-	-	-1,874,260	-	-	-	-	1,721,722	-	-4,056,000	-4,390,000	-4,410,000	-4,400,000	-3,787,000	-3,714,000	-3,741,000
EBT Margin	-496.3%	-232	-39.06	-19.75	-11.49	-12.03	-18.88	-17.61	-32.25	-33.23	-22.42	-	-	-	-	-	-	-	-	-	-	-
Net Income	-13.7%	-3,622,785	-3,187,275	-9,495,996	-3,073,394	-2,773,678	-3,005,404	-3,005,404	-1,874,260	56,300	2,836,495	-15,245,609	-3,518,600	-346,899	-577,379	-4,056,000	-4,390,000	-	-	-	-	-
Net Income Margin	-243.5%	-232	-67.83	-33.97	-12.76	-12.02	-9.80	-2.32	-30.42	-31.65	-44.36	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	24.3%	-3,156,058	-4,171,136	-5,586,545	-2,948,266	-2,340,407	-2,771,899	-2,354,115	-1,848,640	-1,691,428	-1,519,423	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2020Q1	2019Q4	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-47.0%	3,326	6,277	10,276	12,790	9,910	14,780	17,901	4,553	7,690	9,774	11,628	13,240	14,803	1,430	2,130	2,629	3,127	5,165	4,930	3,654	3,715
Current Assets	-49.2%	2,791	5,496	9,813	12,242	9,279	14,072	17,119	3,695	6,761	8,792	10,726	12,287	13,800	428	986	90.00	1,818	3,773	3,533	3,385	3,580
Cash Equivalents	-51.3%	2,520	5,175	9,080	11,200	8,274	13,860	16,809	3,357	6,129	8,500	10,349	12,034	13,553	279	727	57.00	1,427	3,290	3,283	3,069	3,018
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00
Net PPE	-6.9%	19.00	20.00	19.00	19.00	21.00	19.00	16.00	17.00	17.00	-	-	-	-	16.00	93.00	-	186	202	140	148	135
Liabilities	19.8%	5,947	4,966	5,041	5,157	8,560	4,223	4,635	2,585	2,905	2,072	2,110	12,465	16,959	3,309	2,469	1,466	2,410	2,953	3,506	2,356	3,124
Current Liabilities	20.5%	5,625	4,668	5,041	5,000	6,572	3,908	4,192	2,016	2,250	1,334	1,381	11,717	1,318	2,539	1,684	1,466	1,550	2,018	2,531	2,297	3,057
Shareholder's Equity	-100.0%	-	1,300	5,234	7,633	1,350	10,557	13,267	-	2,803	5,756	7,608	-	-	-	-	-	717	2,212	1,424	1,298	591
Retained Earnings	-7.8%	-56,400	-52,325	-48,263	-44,600	-41,453	-32,000	-28,884	-26,091	-23,100	-20,100	-18,245	-19,055	-21,909	-90,200	-88,221	-3,075	-86,916	-84,803	-82,157	-78,534	-74,478
Additional Paid-In Capital	0.2%	53,619	53,488	53,350	52,141	42,740	42,451	42,088	26,004	25,853	25,839	25,826	18,000	17,904	88,351	87,881	-	87,618	87,001	83,571	79,823	74,877
Shares Outstanding	1.3%	3,047	3,008	2,969	2,671	1,275	1,273	1,272	733	733	702	543	378	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	20,000	-	-	-	44,600	-	-	-	12,100	-	-	-	-	5,900	-	-	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2020Q1	2020Q1	2019Q4	2019Q4	2019Q3	2019Q3	2019Q2
Cashflow From Operations	30.9%	-2,697,019	-3,902,981	-3,154,921	-4,171,136	-5,584,117	-2,944,747	-2,340,406	-2,770,999	-2,354,115	-1,848,640	-1,691,428	-1,519,423	-4,002,462	-1,080,000	-1,609,152	-9,084,073	-	-8,326,104	-	-6,455,246	-94,754
Share Based Compensation	-4.4%	131,504	137,526	172,557	224,547	283,927	368,282	340,409	187,736	49,433	58,515	61,732	95,525	-61,338	123,000	18,217	666,433	-	555,567	-	350,893	17,107
Cashflow From Investing	100.1%	1.00	-1,961	-1,137	-	-2,428	-3,519	-1.00	-900	-	-	-	-	-2,736,214	77,000	-1,250,000	290,000	-	40,000	-	20,000	-50,000
Cashflow From Financing	-	-	-	1,051,408	7,082,484	-	-	-	-	-	-	6,375	-	20,682,772	555,000	3,700,000	6,395,000	-	6,529,000	-	6,551,000	250,000

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TMBR Income Statement

2023-06-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total revenue	$ 0	$ 0	$ 0	$ 83,177
Operating costs and expenses
Research and development	2,471,221	3,891,500	4,836,972	5,410,459
Milestone expense for Patagonia Pharmaceuticals, LLC	0	4,000,000	0	4,000,000
Selling, general and administrative	1,370,111	1,512,343	3,004,790	3,214,738
Impairment charge for right of use asset	157,421	0	157,421	0
Total operating expenses	3,998,753	9,403,843	7,999,183	12,625,197
Loss from operations	(3,998,753)	(9,403,843)	(7,999,183)	(12,542,020)
Other income (expense)
Interest expense	(65,098)	(42,077)	(128,075)	(96,328)
Interest income	13,836	0	13,836	0
Other income	0	0	0	75,000
Forgiveness of PPP loan	0	0	0	37,772
Gain (loss) on foreign currency exchange	(13,335)	(50,076)	(11,180)	(43,814)
Total other income (expense)	(64,597)	(92,153)	(125,419)	(27,370)
Net loss and comprehensive loss	(4,063,350)	(9,495,996)	(8,124,602)	(12,569,390)
Net loss attributable to common stockholders	$ (4,063,350)	$ (9,495,996)	$ (8,124,602)	$ (12,569,390)
Basic and diluted net loss per share attributable to common stockholders (in dollars per share)	$ (1.32)	$ (7.45)	$ (2.65)	$ (9.87)
Basic and diluted weighted average number of shares outstanding (in shares)	3,081,110	1,274,632	3,061,594	1,273,698

TMBR Balance Sheet

2023-06-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 2,519,501	$ 9,080,426
Prepaid research and development	138,838	525,532
Other current assets	132,766	207,171
Total current assets	2,791,105	9,813,129
Deposits	145,137	127,534
Property and equipment, net	18,663	19,373
Right of use asset	371,308	315,932
Total assets	3,326,213	10,275,968
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	1,631,597	1,350,793
Accrued expenses	2,020,571	1,609,535
Lease liability, current portion	222,336	331,152
Short-term milestone payable due to Patagonia Pharmaceuticals LLC	1,750,000	1,750,000
Total current liabilities	5,624,504	5,041,480
Lease liability	322,793	0
Total liabilities	5,947,297	5,041,480
Commitments and contingencies (Note 7)
Preferred stock par value $0.001; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	0	0
Common stock, par value $0.001; 450,000,000 shares authorized; 3,047,431 shares issued and outstanding as of June 30, 2023, and 2,969,272 shares issued and outstanding as of December 31, 2022	148,432	148,354
Additional paid-in capital	53,619,078	53,350,126
Accumulated deficit	(56,388,594)	(48,263,992)
Total stockholders' (deficit) equity	(2,621,084)	5,234,488
Total liabilities and stockholders' (deficit) equity	$ 3,326,213	$ 10,275,968

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

CEO	Mr. John Koconis M.B.A.
WEBSITE	timberpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Timber Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Timber Pharmaceuticals, Inc.? What does TMBR stand for in stocks?

TMBR is the stock ticker symbol of Timber Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Timber Pharmaceuticals, Inc. (TMBR)?

As of Wed Jan 31 2024, market cap of Timber Pharmaceuticals, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMBR stock?

You can check TMBR's fair value in chart for subscribers.

What is the fair value of TMBR stock?

You can check TMBR's fair value in chart for subscribers. The fair value of Timber Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Timber Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMBR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Timber Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether TMBR is over valued or under valued. Whether Timber Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Timber Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMBR.

What is Timber Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jan 31 2024, TMBR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMBR PE ratio will change depending on the future growth rate expectations of investors.